{'52WeekChange': -0.13359785,
 'SandP52WeekChange': 0.0644362,
 'address1': '100 Binney Street',
 'address2': 'Suite 710',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.4,
 'askSize': 3000,
 'averageDailyVolume10Day': 101800,
 'averageVolume': 132368,
 'averageVolume10days': 101800,
 'beta': None,
 'beta3Year': None,
 'bid': 13.4,
 'bidSize': 1100,
 'bookValue': 6.094,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.74,
 'dayLow': 12.95,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.388,
 'enterpriseToRevenue': None,
 'enterpriseValue': 189023744,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 15.324857,
 'fiftyTwoWeekHigh': 21.06,
 'fiftyTwoWeekLow': 5.84,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 7152950,
 'forwardEps': -2.94,
 'forwardPE': -4.4557824,
 'fromCurrency': None,
 'fullTimeEmployees': 87,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.055760004,
 'heldPercentInstitutions': 0.84466004,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/tcr2.com',
 'longBusinessSummary': 'TCR2 Therapeutics Inc., a clinical-stage '
                        'immunotherapy company, develops novel T cell receptor '
                        'therapies for patients suffering from cancer. The '
                        "company's lead product candidates include TC-210, "
                        'mono TCR Fusion Construct T cells (TRuC-T cells) '
                        'targeting mesothelin positive solid tumors, which '
                        'initiated in phase I/II clinical trial for the '
                        'treatment of non-small cell lung cancer (NSCLC), '
                        'ovarian cancer, malignant pleural/peritoneal '
                        'mesothelioma, and cholangiocarcinoma; and TC-110 a '
                        'TRuC-T cell targeting CD19-positive B-Cell '
                        'hematological malignancies. Its product candidates in '
                        'pipeline focuses on adult acute lymphoblastic '
                        'leukemia, diffuse large B-cell lymphoma, and '
                        'follicular lymphoma areas. The company was formerly '
                        'known as TCR2, Inc. and changed its name to TCR2 '
                        'Therapeutics Inc. in November 2016. TCR2 Therapeutics '
                        'Inc. was founded in 2015 and is headquartered in '
                        'Cambridge, Massachusetts.',
 'longName': 'TCR2 Therapeutics Inc.',
 'market': 'us_market',
 'marketCap': 315394304,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_316867676',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -53202000,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.64,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 949 5200',
 'previousClose': 13.66,
 'priceHint': 2,
 'priceToBook': 2.1496556,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.74,
 'regularMarketDayLow': 12.95,
 'regularMarketOpen': 13.64,
 'regularMarketPreviousClose': 13.66,
 'regularMarketPrice': 13.64,
 'regularMarketVolume': 104129,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 24075900,
 'sharesPercentSharesOut': 0.038,
 'sharesShort': 914981,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 519371,
 'shortName': 'TCR2 Therapeutics Inc.',
 'shortPercentOfFloat': 0.056700002,
 'shortRatio': 4.98,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'TCRR',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.214,
 'twoHundredDayAverage': 12.236654,
 'volume': 104129,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.tcr2.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}